Wego Holding Co., Ltd. (“WEGO”) and together with its subsidiaries (“WEIGAO GROUP”) is situated in Weihai City, a picturesque coastal city in China. Shandong WEIGAO GROUP Medical Polymer Company Limited (“WEIGAO GROUP”), the major subsidiary of WEGO, is listed on the Stock Exchange of Hong Kong Limited. The business of WEGO now covers medical device, pharmacy, aerospace electronic products, investment and real estate. WEGO has more than 16,000 employees and a total asset value of over RMB 20 billion. WEGO currently produces about 400 types of medical products with more than 30,000 specifications. With a great variety of products and good quality, WEGO has become one of the most reliable suppliers for medical solutions in the world.
Rooted with the spirit of “development, innovation, pragmatism and consolidation”, WEGO has established manufacturing bases for medical consumables, orthopedics products, pharmaceuticals and aerospace electronic products. In the domestic market, the company was the early mover to initiate the products of single use transfusion sets, intravenous catheters, pre-filled syringes, blood storage and segregation consumables, blood purification consumables, ICU and cardio intervention consumables, orthopedic products, operation room consumables, blood sampling and diagnostic consumables, IV solutions and medicine, electronic and mechanical medical products, PVC granules and medical needles.
WEGO is devoted to innovation, technology and people and its commitment to technology is the value to its development. WEGO was accredited by the State Science and Technology Commission as the “Key High Technology & New Technological Enterprise under the State Torch Program”, the “Preferred Manufacturing Base for New Products Developed by the State High Technology Research Development (863) Program”. WEGO continues to develop into a conglomerate enterprise comprising of duties and responsibilities of manufacturing, education and research. The company has established state enterprise technology center, national engineering laboratory, academician research center, post-doctoral research center and provincial medical materials engineering research center and collaborated with scientific research institutions and universities with strong scientific and research strength in setting up nine research and development centers, ten academicians were appointed as consultants. Meanwhile, WEGO established a number of R&D centers in Germany, the U.S., Japan, Britain and France.
The company has been engaged in more than 20 national projects including Project 863, Project Torch, Model Project of National High Tech, The Key Technology Innovation Program of the State, and other projects. Currently, WEGO plays roles in the market of drug eluting stent (DES), pre-filled syringes and orthopedic products which were previously dominated by international players. The technology of chemical, biological modification, and large-scale utilization for polyolefin material project’ jointly developed by WEGO HOLDING CO., LTD. and Chang Chun Institute of Applied Chemistry of Chinese Academy of Sciences was awarded the Second Prize of the National Prize for Progress in Science and Technology.
WEGO has been persistently sustaining its brand value. The “Jierui” trademark was notarized as “China Famous Brand” by State Administration for Industry & Commerce, and as “the Most Famous Branded Product in China” by Inspection and Quarantine of China, and as “the No.1 Trademark” in the industry by China Brand Academy. WEGO has an extensive coverage of over 100 representative offices in more than 30 provinces, municipality and autonomous regions in China. Long term reliable relationship has also been well established with more than 7,000 hospitals, over 400 blood stations and over 1800 other medical units. Today, WEGO’s products are not just the best-selling products in the domestic market; they are also exported to more than 70 countries and regions, including the United States, European countries, Russia, South Africa and Brazil.
WEGO will continue to strive for development while adhering to Scientific Outlook on Development. WEGO’s mission is “Your Health, We Care”. WEGO’s core value is “Conscience, Integrity and Loyalty”. WEGO’s shared value is “Generosity, Harmony, Responsibility and Innovation”. WEGO’s vision is “Striving to be an internationally competitive, leading in Asia, and most respected conglomerate in medical device and pharmaceutical products.” WEGO is well-positioned to continuing serving the medical community and improve people’s health for generations to come.
Contact Us:
Tel: 0086-631-5620486 Fax: 0086-631-5620555
Website: http://www.weigaoholding.com/